Previsioni di mercato delle malattie cardiometaboliche in Medio Oriente e Africa fino al 2028 – Impatto del COVID-19 e analisi regionale per tipologia (malattie cardiovascolari (CVD), diabete di tipo 2, ipertensione e obesità), trattamento (ACE inibitori, diuretici, glucofagi e altri), Dosaggio (compresse e iniezione), via di somministrazione (orale ed endovenosa), utenti finali (ospedale, clinica e assistenza domiciliare) e canale di distribuzione (farmacia ospedaliera, farmacia al dettaglio e farmacia online)
Introduzione al mercato
La malattia cardiometabolica è caratterizzata da un gruppo di anomalie e sintomi che aumentano il rischio che gli individui sviluppino malattie cardiovascolari. Ipertensione, obesità, resistenza all’insulina, dislipidemia, basso profilo di colesterolo (LDL) e tolleranza al glucosio sono alcuni dei sintomi. Gli individui affetti da sindrome cardiometabolica sono soggetti a numerose altre malattie potenzialmente letali come il diabete di tipo 2, ictus, malattia coronarica (CAD), malattie cardiovascolari (CVD) e molte altre.
Inoltre, si prevede che la crescente prevalenza delle malattie cardiometaboliche rafforzerà la crescita del mercato durante il periodo di previsione. Tuttavia, la sottodiagnosi delle malattie cardiovascolari nei paesi a basso e medio reddito (LMIC) limita la crescita del mercato delle malattie cardiometaboliche in Medio Oriente e Africa.
La pandemia ha aumentato la domanda di dispositivi medici che possono essere utilizzati in ambito domiciliare. La regione ha osservato un numero crescente di pazienti ricoverati nelle unità di terapia intensiva (ICU). Un numero crescente di farmaci impone molteplici sfide diagnostiche e terapeutiche ai sistemi sanitari sotto pressione, portando ad un aumento dei dispositivi medici e dei prodotti farmaceutici. Inoltre, è aumentato il numero crescente di casi di patologie croniche, il che ha comportato un maggiore utilizzo di farmaci per combattere il virus. Durante la diffusa pandemia di COVID-19, ci sono state preoccupazioni circa il potenziale di alcuni farmaci per la pressione sanguigna come gli inibitori dell’enzima di conversione dell’angiotensina (ACEi) e i bloccanti della conversione dell’angiotensina (ARB). L’attuale sindrome respiratoria acuta grave coronavirus 2 (SARS-CoV-2) utilizza i recettori dell’enzima di conversione dell’angiotensina 2 (ACE2) legati alla membrana per facilitare l’ingresso nella cellula ospite. Questa pandemia ha migliorato le operazioni commerciali dei vari produttori di farmaci che operano nel mercato delle malattie cardiometaboliche nella regione.
Panoramica e dinamiche del mercato
Si prevede che il mercato delle malattie cardiometaboliche in Medio Oriente e Africa raggiungerà i 5.008,5 milioni di dollari entro il 2028 rispetto ai 4.300,9 milioni di dollari del 2021; si prevede che crescerà a un CAGR del 2,2% dal 2021 al 2028. La pipeline di farmaci candidati basati sulla CMD si sta espandendo per un\'ampia gamma di applicazioni terapeutiche, tra cui ipertensione, diabete e disturbi infiammatori. Molte aziende farmaceutiche grandi e piccole sono coinvolte nello sviluppo di numerosi farmaci a piccole molecole. Ad esempio, AstraZeneca dispone di più di 25 terapie e combinazioni terapeutiche nella sua fase cardiovascolare, renale e metabolica (CVRM) dalla fase iniziale a quella avanzata. Basati su tecnologie avanzate, vengono introdotti numerosi prodotti per il trattamento delle CMD. Inoltre, i crescenti investimenti nella ricerca relativa alle CMD stanno dando una spinta significativa al mercato delle malattie cardiometaboliche. Tutti questi investimenti si riflettono positivamente sulla crescita del mercato delle malattie cardiometaboliche in Medio Oriente e Africa.
Segmenti chiave del mercato
In termini di tipologia, il segmento delle malattie cardiovascolari ha rappresentato la quota maggiore del mercato delle malattie cardiometaboliche in Medio Oriente e Africa nel 2020. In termini di trattamento, il segmento degli ACE inibitori ha rappresentato per la quota maggiore del mercato delle malattie cardiometaboliche in Medio Oriente e Africa nel 2020. In termini di dosaggio, il segmento delle compresse ha rappresentato la quota maggiore del mercato delle malattie cardiometaboliche in Medio Oriente e Africa nel 2020. In termini di via di somministrazione, la via orale Il segmento ospedaliero ha rappresentato la quota maggiore del mercato delle malattie cardiometaboliche in Medio Oriente e Africa nel 2020. In termini di utente finale, il segmento ospedaliero ha rappresentato la quota maggiore del mercato delle malattie cardiometaboliche in Medio Oriente e Africa nel 2020. Inoltre, in base al canale di distribuzione , il segmento delle farmacie ospedaliere ha detenuto la quota di mercato maggiore nel 2020.
Principali fonti e aziende elencate
Alcune delle principali fonti primarie e secondarie a cui si fa riferimento per la preparazione di questo rapporto sul mercato delle malattie cardiometaboliche in Medio Oriente e Africa sono siti Web aziendali, relazioni annuali, relazioni finanziarie, documenti governativi nazionali e database statistici, tra gli altri. Le principali aziende elencate nel rapporto sono Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S e AstraZeneca.
Rapporto sui motivi per acquistare
- Comprendere il mercato delle malattie cardiometaboliche in Medio Oriente e Africa panorama e identificare i segmenti di mercato che potrebbero garantire un forte rendimento
- Comprendere il panorama del mercato in continua evoluzione e rimanere al passo con la concorrenza
- Pianificare in modo efficiente fusioni, acquisizioni e accordi di partnership nel mercato delle malattie cardiometaboliche in Medio Oriente e Africa identificando i segmenti con le vendite probabili più promettenti
- Fare affari consapevoli decisioni derivanti da un\'analisi perspicace e completa dell\'andamento del mercato dei vari segmenti
- Ottenere previsioni sui ricavi di mercato del mercato delle malattie cardiometaboliche in Medio Oriente e Africa in base a vari segmenti per il periodo 2021-2028
SEGMENTAZIONE DEL MERCATO DELLE MALATTIE CARDIOMETABOLICHE IN MEDIO ORIENTE E AFRICA
< p>Per tipo- Malattie cardiovascolari (CVD)
- Diabete di tipo 2
- Ipertensione
- Obesità
< span>Per trattamento
- ACE inibitori
- Diuretici
- Glucophage
- Altri
Per dosaggio
- Tablet
- Iniezione
- Orale
- Per via endovenosa
Da parte degli utenti finali
- Ospedale
- Clinica
- Impostazioni per l\'assistenza domiciliare
Di Canale di distribuzione
- Farmacia ospedaliera
- Farmacia al dettaglio
- Farmacia online
Per paese
- Medio Oriente e Africa
- Emirati Arabi Uniti
- Arabia Saudita
- Sudafrica
- Resto del Medio Oriente e dell\'Africa
Società menzionate
- Bayer AG
- Novartis AG ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Middle East and Africa Cardiometabolic Diseases market – By Country
2. Middle East and Africa Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East and Africa Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Middle East and Africa Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Middle East and Africa Cardiometabolic Diseases Market – Regional Analysis
6.1 Middle East and Africa Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Middle East and Africa Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Middle East and Africa Cardiometabolic Diseases Market – Geographic Analysis
13.1 Middle East and Africa: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 Middle East & Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.1.3 Middle East & Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 Middle East & Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 Middle East & Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 Middle East & Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 Middle East & Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.8 Middle East & Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9 Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.9.1.1 Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.10 Saudi Arabia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.11 Saudi Arabia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.12 Saudi Arabia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.13 Saudi Arabia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.14 Saudi Arabia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.15 Saudi Arabia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.15.1 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.15.1.1 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.15.1.2 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.16 UAE: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.17 UAE: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.18 UAE: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.19 UAE: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.20 UAE: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.21 UAE: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.21.1 South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.21.1.1 South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.22 South Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.23 South Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.24 South Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.25 South Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.26 South Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.27 South Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.27.1 Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.27.1.1 Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.28 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.29 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.30 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.31 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.32 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.33 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Middle East and Africa Cardiometabolic Diseases Market
14.1 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
15. Middle East and Africa Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Bayer AG
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Novartis AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Boehringer Ingelheim International GmbH
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novo Nordisk A/S
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 AstraZeneca
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Middle East & Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 3. Middle East & Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Middle East & Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 5. Middle East & Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 6. Middle East & Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. Saudi Arabia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Saudi Arabia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 9. Saudi Arabia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Saudi Arabia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 11. Saudi Arabia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 12. Saudi Arabia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. UAE Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. UAE Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. UAE Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. UAE Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 17. UAE Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 18. UAE Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 19. South Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. South Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. South Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. South Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 23. South Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 24. South Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 27. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 29. Rest of Middle East and Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 30. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 31. Organic Developments in the Cardiometabolic Diseases Market
Table 32. Inorganic Developments in the Cardiometabolic Diseases Market
Table 33. Glossary of Terms, Middle East and Africa Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Middle East and Africa Cardiometabolic Diseases Market Segmentation
Figure 2. Middle East and Africa Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Middle East and Africa Cardiometabolic Diseases Market
Figure 4. Middle East and Africa Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Middle East and Africa Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Middle East and Africa PEST Analysis
Figure 7. Middle East and Africa Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Middle East and Africa Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Middle East and Africa: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. Middle East & Africa Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Million)
Figure 35. Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Impact of COVID-19 Pandemic on Middle East and Africa Cardiometabolic Diseases Market
Figure 41. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East and Africa cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East and Africa cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.